Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non–small-cell Lung Cancer: LAURA Trial in Progress-Reference-Cited by-同舟云学术

Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non–small-cell Lung Cancer: LAURA Trial in Progress

Published:2021-07 Issue:4 Volume:22 Page:371-375
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Lu Shun,Casarini Ignacio,Kato Terufumi,Cobo Manuel^ORCID,Özgüroğlu Mustafa,Hodge Rachel,van der Gronde Toon^ORCID,Saggese Matilde,Ramalingam Suresh S.

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference19 articles.

1. ICBP Module 1 Working Group. Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004–2007;Walters;Thorax,2013

2. ESMO Guidelines Committee. Early-stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines;Postmus;Ann Oncol,2017

3. Panel Members. 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer;Eberhardt;Ann Oncol,2015

4. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis;Zhang;Oncotarget,2016

5. The impact of epidermal growth factor receptor mutations on patterns of disease recurrence after chemoradiotherapy for locally advanced non–small cell lung cancer: a literature review and pooled analysis;Ochiai;J Radiat Res,2016

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC;New England Journal of Medicine;2024-08-15

2. A prospective analysis of the management practices for patients with Stage-III-N2Non-Small-Cell lung cancer (OBSERVE IIIA–B GFPC 04-2020Study);Lung Cancer;2024-08

3. Advancements in non-small cell lung cancer treatment: from early to advanced stages;Oncology in Clinical Practice;2024-06-24

4. American Radium Society Appropriate Use Criteria for Unresectable Locally Advanced Non–Small Cell Lung Cancer;JAMA Oncology;2024-06-01

5. The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC;The Oncologist;2024-05-18